Imaging, Blood, and Tissue Samples to Guide Colon Cancer and Liver Tumor Care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects imaging data, blood samples, and tissue specimens from patients undergoing surgery for colon cancer or related liver tumors to explore new ways to diagnose the disease and predict its spread. It analyzes how these data points relate to disease biology and potential treatment decisions. The study does not assign treatments but seeks to identify biomarkers and patterns that could guide future care. Participants are adults undergoing colectomy, hepatectomy, or related abdominal procedures as part of routine care at MSK locations. Pathology and imaging results will be correlated to explore how best to inform clinical management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must be undergoing one of the following procedures as part of their routine care in order to meet the inclusion criteria:

  * Operation for presumed stage I-IV colon cancer including colectomy, hepatectomy, or abdominal surgery (e.g. insertion of HAIP)
  * Colectomy for presumed benign or pre-malignant colon tumors (e.g. large nonneoplastic polyps or adenomas)
* Open, laparoscopic, or robotic resections
* ≥18 years old

Exclusion Criteria:

* Extrahepatic CRC metastasis
* No preoperative portal venous phase CT scan performed up to two months prior to day of surgery Pathology demonstrating a malignant tumor other than colorectal adenocarcinoma.
* Stage IV colon cancer with resectable hepatic disease undergoing hepatectomy with active primary colon tumor still in place (despite chemo-radiation therapy) and no plans for colectomy.
* Receipt of experimental therapies for colon cancer (e.g. checkpoint inhibitors or novel targeted agents). Of note, approved targeted agents (such as anti-angiogenic agents, EGFR inhibitors etc) are not an exclusion criterion.
* History of non-colonic malignancy w/in 5 years (except non-melanomatous skin cancer)
* Colon cancer with microsatellite instability (MSI-high) if known preoperatively
* Known hereditary colon cancer syndrome such as familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC)
* Known liver disease (e.g. non-alcoholic steatohepatitis, cirrhosis, viral or other form of hepatitis, etc)
* INR \>2 or known clotting factor deficiency
* Anticipated need for full anticoagulation during hospitalization
* Receipt of medications that increase significantly the risk of bleeding after liver biopsy (at the surgeon"s discretion)
* Intraoperative discovery of pathology that precludes the planned surgical resection or liver biopsy, or makes resection futile (such as peritoneal carcinomatosis or other extrahepatic metastatic disease)
* Operating surgeon deems research interventions to be more than a minimal risk for the patient

Where it's running

• Memorial Sloan Kettering Basking Ridge
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Michael D'Angelica — Memorial Sloan Kettering Cancer Center
• Study coordinator: Michael D'Angelica, MD
• Email: dangelim@mskcc.org
• Phone: 212-639-3226

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.